Growth opportunities ProAxsis is a small, early-stage pharmaceutical biomarker firm with recent office expansion and leadership changes, indicating a growing commercial push and potential interest in strategic partnerships, channel collaborations, or contract research support.

Respiratory biomarker focus Specialization in active protease biomarkers and respiratory disease translational research positions ProAxsis to partner on COPD, asthma, and related respiratory clinical trials, offering opportunities for assay development, sampling services, and remote monitoring tools.

Remote monitoring potential Recent Innovate UK grant and press coverage around developing remote respiratory monitoring tools suggest appetite for collaboration with technology providers, data analytics partners, and cloud-based biomarker data platforms.

Strategic partnerships Partnership with COPD Foundation and collaboration in digital health CSR programs highlight a willingness to engage with health organizations and patient-centric initiatives, creating avenues for co-development, funded studies, and sponsored biomarker insights.

Funding and capability build Low revenue and early-stage funding history with recent £1.8m product development financing and lab expansion imply a need for customer development, pilot projects, and scale-ready opportunities to showcase value quickly to attract further investment.